Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.

Zabkiewicz J. et al, (2020), Br J Haematol

Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.

Linch DC. et al, (2020), Br J Haematol, 188, 852 - 859

Molecular MRD status and outcome after transplantation in NPM1-mutated AML.

Dillon R. et al, (2020), Blood, 135, 680 - 688

The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.

Linch DC. et al, (2020), Br J Haematol

Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.

Hills RK., (2020), Br J Haematol, 188, 29 - 35

Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?

Burnett AK. et al, (2020), Br J Haematol, 188, 86 - 100

Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL.

Elston L. et al, (2019), Br J Haematol

Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

Sasca D. et al, (2019), Blood

Mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Eiring AM. et al, (2019), CANCER RESEARCH, 79

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452

Correction: High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M. et al, (2019), Blood Cancer J, 9

Real world data and the art of maintenance therapy.

Hills RK., (2019), Br J Haematol, 184, 493 - 494

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.

Burnett AK. et al, (2018), Leukemia, 32, 2693 - 2714

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Hills RK. et al, (2018), BLOOD, 132

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) - the UK Monocle Study

Knapper S. et al, (2018), BLOOD, 132

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Dillon R. et al, (2018), BLOOD, 132

The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial

Burnett AK. et al, (2018), Haematologica, 103, 1654 - 1661

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.

Russell N. et al, (2018), Blood, 132, 1452 - 1454

High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.

Marquis M. et al, (2018), Blood Cancer J, 8

Potential benefit of higher dose daunorubicin in patients harbouring a FLT3-ITD mutation: Updated results of the AML17 trial

Russell NH. et al, (2018), British Journal of Haematology, 173, 9 - 9

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?